

Malarial Morbidity and Postnatal HIV Infection in Breastfeeding HIV-exposed Infants

Amara E. Ezeamama, PhD^{1*}, Christopher Duggan, MD^{2,3}, Donna Spiegelman, ScD^{4,5}, Ellen Hertzmark, MS⁵, Ronald J. Bosch, PhD⁶, Karim P. Manji, MMED⁷, Roland Kupka, ScD^{2,8}, Melanie W. Lo, MD⁹, James O. Okuma, MS², Rodrick Kisenge, PhD⁷, Said Aboud, MD^{7,10}, Wafaie W. Fawzi, DrPH^{2,4,11}

¹Department of Epidemiology & Biostatistics, The University of Georgia, B.S. Miller Hall Room 125, 101 Buck Rd, Athens, GA 30602, USA;

²Department of Nutrition, Harvard School of Public Health (HSPH), Boston, MA

³Division of Gastroenterology and Nutrition, Children's Hospital, Boston, MA

⁴Department of Epidemiology, HSPH, Boston, MA

⁵Department of Biostatistics, HSPH, Boston, MA

⁶Center for Biostatistics in AIDS Research, HSPH, Boston, MA

⁷Department of Pediatrics and Child Health, School of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.

⁸United Nations Children's Fund, Regional Office for West and Central Africa, PO Box 29720, Dakar-Yoff, Senegal

⁹University of Minnesota Medical School, MN, USA

¹⁰Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, United Nations Road, Upanga, P.O. Box 65001, Dar es Salaam, Tanzania.

¹¹Department of Global Health and Population, HSPH, Boston, MA

ABSTRACT

Background: For at-risk HIV-negative individuals, whether malarial morbidity increases the likelihood of HIV infection when exposed is unknown. Hence, we investigate the malaria-associated risk of postnatal HIV infection in 1804 breastfeeding infants of HIV-positive women from Dar es Salaam, Tanzania.

Methods: Six-week-old HIV-negative infants were followed until breastfeeding cessation or postnatal HIV infection. HIV-1 status was determined by a DNA PCR test. Malarial morbidity was diagnosed by physicians using a combination of clinical symptoms and laboratory tests. For analytic purposes, malaria was distinguished by diagnostic specificity as: (1) clinical; (2) probable, where laboratory testing is requested for parasitemia; and (3) blood smear-confirmed. Hazard ratios (HR) and 95% confidence intervals (CIs) for the risk of HIV infection were estimated from multivariate Cox regression models.

Results: Mean follow-up duration was 6.2 months (SD=2.4 months), during which 91 new HIV infections developed and clinical malaria was diagnosed in 594(32.3%) children, including 283 (15.5%) probable and 80(4.4%) confirmed malaria episodes. Infants ever diagnosed with clinical and probable malaria were at 73% (95%CI:1.11 - 2.69) and 100% (95%CI:1.17-3.42) higher risk of postnatal HIV infection, respectively. This risk increased by 39% (95%CI: 1.08-1.80) and 59% (95%CI: 1.00-2.32), respectively, per episode increment in clinical and probable malarial; however, confirmed malaria was not significantly associated

with HIV incidence (HR=2.09; 95%CI: 0.74 - 5.91).

Conclusion: We found positive associations between child malarial infection and postnatal HIV infection among breastfeeding HIV-negative children of HIV-positive women. These findings suggest that malaria prevention in such infants may decrease the risk of HIV mother-to-child-transmission. However, specific future studies using laboratory-confirmed malaria in HIV-negative but HIV at risk populations are needed to substantiate these findings.

Keywords: HIV/AIDS, Malaria, Co-infection, Children, HIV Incidence, Breastfeeding, Children, Sub-Saharan Africa

1. INTRODUCTION

Malaria and human immunodeficiency virus (HIV) are leading causes of death in Sub-Saharan Africa (SSA)(1), where millions are at risk of co-infection.(2) Up to a 30% co-infection rate has been reported in HIV-infected adults,(3) among whom frequent and severe malaria episodes, CD4 T-cell count declines, and higher viral loads were observed.(4) For at-risk HIV-uninfected individuals, whether malaria promotes HIV acquisition is unknown(5), with no epidemiologic evidence that the malaria-associated decline in CD4 T-cell count(6, 7) and increase in viral load(4) correlate with HIV incidence. However, results from CD4 T-cell infectability studies within *Plasmodium falciparum* antigen-stimulated pro-inflammatory cytokine milieu(8) suggest that immune responses to malaria in at-risk HIV-negative persons promotes HIV infection through parasite-induced immune activation,(9) up-regulation of viral expression in macrophages,(10) and enhanced expression of CCR5 and CXCR4 co-receptors that facilitate HIV cell entry.(11)

Women of reproductive age constitute the majority of HIV-infected persons in SSA.(12) Many bear children and breastfeed post-delivery despite the breastfeeding-associated risk of HIV mother-to-child-transmission (MTCT).(13) Breastfeeding of HIV-exposed but uninfected infants by their HIV-positive mothers has serious health implications for the newborn's health. In the malaria-endemic regions of SSA, in particular, such a newborn is at simultaneous high risk of malaria and HIV infections. On the one hand, the passive anti-malaria immunity transferred through breastfeeding is highly desirable because it will protect the newborn from malaria;(14) on the other hand, for infants of HIV-positive women, the shedding of HIV virus in breast milk is a serious risk factor for postnatal HIV infection.(15) The World Health Organization's (WHO) prevention of MTCT guidelines attempts to balance this inherent tension, while optimizing the likelihood of HIV-free survival for infants of HIV-positive women. WHO recommends exclusive breastfeeding in tandem with antiretroviral therapy (ART) prophylaxis for the mother and child during breastfeeding for 6 months.(15) Despite the near-universal breastfeeding and the dual threat of HIV and malaria infections for infants of HIV-positive women in SSA, how malaria affects postnatal HIV infection has not been specifically investigated. Therefore, we conduct this prospective cohort study to test the hypothesis that malarial morbidity in HIV-uninfected breastfeeding babies of HIV-positive mothers increases their risk of postnatal HIV infection.

2. MATERIAL AND METHODS

Design

This is a nested prospective cohort study designed to investigate the association between child malarial morbidity and postnatal HIV infection in breastfeeding HIV-negative children of HIV-positive women. The parent study is a randomized, placebo-controlled trial of the efficacy of daily supplementation with vitamins B, C, and E in decreasing the incidence of select childhood morbidities among infants of HIV-positive women in Dar es Salaam, Tanzania. The parent study included follow-up of the mother-child pair until the child's 24th month of life. For this nested study, follow-up duration is restricted to the period of breastfeeding, when infants of HIV-positive women are at risk of postnatal HIV MTCT.

Setting

Malaria is endemic in Dar es Salaam, with stable transmission year round. The annual prevalence of malaria in Dar es Salaam is 12%, with an estimated 1.28 infectious mosquito bites per person per year.⁽¹⁶⁾ Among children less than 5 years old, malaria is identified as the cause of one in three deaths and is the primary reason for at least 40% of medical consultations.⁽¹⁷⁾ With respect to HIV prevalence in the study area at study initiation, HIV prevalence in antenatal clinics was 8.4%,⁽¹⁸⁾ and pediatric HIV constituted 9% of prevalent HIV infections.

Inclusion/Exclusion Criteria for Study Participation

Pregnant women who intended to maintain residence in Dar es Salaam for two or more years post-delivery and who received medical care during pregnancy at either the Makuti or Tama Study Clinics as part of the Muhimbili, Dar es Salaam and Harvard research collaboration project were enrolled in the parent study between February 2004 and July 2007. Children whose mothers were unable to return for follow-up, those with serious congenital anomalies that would interfere with compliance with study procedures, and those with multiple births were excluded.

All study participants received stipends for transportation to and from the study clinic for monthly scheduled visits, during which medical and detailed nutritional assessments were made. HIV testing, complete blood count, and CD4 measurements were repeated every 6 months. Study participants were encouraged to return to the clinic for management of illnesses that occurred outside of scheduled visits.

Standard of Care

During pregnancy, all mothers received multivitamins, folate, iron, and intermittent preventive malaria therapy that used sulfadoxine-pyrimethamine at the 20th and 30th weeks of gestation. At study initiation, maternal ART was limited to nevirapine administered prophylactically during labor to prevent intra-partum HIV infection. Beginning in July 2005, mothers were routinely evaluated for ART eligibility for their own health as access to antiretroviral drugs widened through the President's Emergency Plan for AIDS Relief (PEPFAR) and other programs. All newborns in the study were given nevirapine within 72 hours of birth or as close to birth as possible for infants not born in hospitals. In addition, all infants were prescribed cotrimoxazole until 6 months of age, after which only breastfeeding and HIV-infected children remained on cotrimoxazole.

115

116 *Primary Determinant: Malarial Morbidity*

117 Malaria was assessed during monthly and unscheduled visits based on physician diagnosis
118 of patients' clinical symptoms as malaria, with or without laboratory testing to confirm
119 parasitemia. All diagnoses were accompanied by anti-malarial prescription, most commonly
120 amodiaquine, sulfadoxine-pyrimethamine, or fansidar. Lab tests were typically ordered in
121 this setting to confirm the presence/absence of treatment-resistant malaria and complicated
122 or cerebral malaria and, thus, reflected heightened clinical suspicion.(19) When diagnosis is
123 accompanied with a requisition for a parasitemia test, children were classified as having
124 clinical malaria if the result of such a test (when available) were either positive or unknown.
125 This approach, which is typical clinical practice in many resource-constrained settings, is
126 consistent with recommendations of the integrated management of childhood illnesses
127 (IMCI). However, such diagnoses are limited by low specificity, which can result in possible
128 over-diagnosis of malarial morbidity.(20) To accommodate this common clinical practice
129 and allow for explicit examination of any differences in our results by malaria diagnostic
130 specificity, we adopted a sensitivity analysis-type approach in defining malarial morbidity, as
131 was done in a previous study.(19) In brief, we created two additional classes of malaria
132 diagnoses, probable and confirmed malaria, based on the requisition of a blood test for the
133 malaria parasite and the presence/absence of laboratory results, given that a test was
134 ordered. Probable malaria included all diagnoses accompanied by a malaria parasite test
135 requisition for which the result of testing was either positive or unknown. Confirmed malaria
136 included the subset of diagnoses accompanied with lab tests, with test results available and
137 positive for parasitemia.

138 Malaria parasite tests were performed using Giemsa-stained thin blood smears made from
139 finger or heel pricks, air dried for 30 minutes. Trained technicians read each blood slide in
140 three different fields, and the parasite density per cubic millimeter was estimated from the
141 number of trophozoites per 200 leukocytes. Malarial morbidity was operationally defined as
142 a time-varying exposure in the following formats: ever vs. never malaria, total malaria
143 episodes to date, and categories of total malaria episodes to date including one, two, or
144 three or more vs. zero episodes. In keeping with previous work, we considered malaria
145 episodes distinct if they occurred 14 days or more apart.(21)

146 *Outcome: Postnatal HIV infection*

147 HIV status of children was assessed at 6 weeks by HIV-1 DNA PCR using Amplicor HIV-1
148 DNA version 1.5 assays (Roche Molecular Systems, Branchburg, NJ, USA) until 18 months
149 of age. Thereafter, HIV status was determined by the Murex HIV antigen/antibody (Abbott
150 Murex, UK), followed by the Enzygnost anti-HIV-1/2 Plus (Dade Behring, Marburg,
151 Germany) ELISAs. Discordant results were resolved through Western blot assay.(22) Per
152 protocol of the parent study, real-time HIV tests were done at 6 weeks and 24 months;
153 however, blood samples for future HIV testing were stored every 6 months. Blood samples
154 for children HIV-positive at 24 months were back-tested to estimate the approximate age at
155 HIV infection. For the purpose of this study, children HIV-negative at 6 weeks were at risk of
156 breastfeeding-related postnatal HIV infection only until the end of breastfeeding only.(15)
157 Hence, we limited child malarial morbidity to those diagnoses that occurred during
158 breastfeeding and up to the date of breastfeeding cessation plus an 8-week sero-conversion
159 window to avoid the confusion of temporal sequence between child malarial morbidity and
160 postnatal HIV infection. Per the literature, it may take up to 56 days for HIV antibodies to
161 appear.(23) Because breastfeeding is the primary risk factor for HIV infection for infants
162 HIV-negative at birth, observations were censored for HIV-positive children at either the first

163 HIV-positive blood sample date or the last breastfeeding date plus 56 days, whichever was
164 sooner.

165

166 *Potential Confounders/Mediators*

167 We considered an extensive array of maternal, child, seasonal, and household factors as
168 potential confounders and/or mediators of the relationship between child malarial morbidity
169 and postnatal HIV infection. Non-time-varying potential confounders measured at baseline
170 included child baseline CD4 T-cell% (<25 vs. $\geq$ 25), child sex, micronutrient supplementation
171 vs. placebo, low birth weight (<2500 vs. $\geq$ 2500g), per-capita household daily food
172 expenditure (<500 vs. >500 Tanzanian Shillings), maternal age (<25, 25-29, 30-34 vs. $\geq$ 35
173 years), education (<7, = 7, vs. >7 years), and history of neonatal mortality in prior
174 pregnancies (yes vs. no). The following time-varying covariates were updated monthly: ever
175 vs. never maternal clinical malaria season of patient visit (long rains (November-February)
176 and short rains (March-May) vs. dry season (June-October), child underweight (weight-for-
177 age z-scores <-2 vs. $\geq$ -2) and cotrimoxazole use (yes vs. no). In addition, child anemia
178 (hemoglobin<10 g/dL), maternal anemia (hemoglobin<11 g/dL), and maternal CD4 T-cell
179 count (<350vs. $\geq$ 350 cells/ μ L) values were time varying and updated bi-annually.

180

181 *Data Analysis*

182 We used Cox proportional hazards models to estimate univariate and multivariable hazard
183 ratios for time-updated malaria infection in relation to the risk of HIV infection. An Anderson-
184 Gill data structure was used to split each child's follow-up period into pieces of person-time,
185 which reflects the interval between two consecutive visits. Within each interval, beginning
186 and end time were defined as child age at the beginning and end of the interval,
187 respectively. Time-varying factors were updated to reflect their values at the beginning of
188 the visit interval. All potential confounders and established risk factors for HIV infection were
189 adjusted for in multivariable models. Missing confounder values were handled using the
190 missing indicator method. Differences in likelihood ratio tests between nested models were
191 used to test for heterogeneity in the malaria-HIV association by child and maternal
192 immunologic and anemia status, micronutrient supplementation, child underweight, maternal
193 WHO HIV disease stage, and pre- vs. post-PEPFAR enrollment. We specified the
194 proportionality test for all time-dependent covariates to examine the Cox proportional
195 hazards assumption and rejected the null hypothesis of equal hazards for strata of specified
196 covariates if associated *p*-values $\leq$ 0.05. All analyses were conducted in SAS version 9.1.

197

198 *Ethical Review & Informed Consent*

199 Ethical clearance for the conduct of this study was provided by the institutional review
200 boards of the Harvard School of Public Health and Muhimbili University of Health and Allied
201 Sciences. The mothers of all children provided written informed consents for their own and
202 their child's participation in the trial.

203 *Role of Funding Source*

The funder of this study had no role in the design, data collection, analysis, interpretation, or writing of this report. The corresponding author had full access to all the data in the study and had the final responsibility for the decision to submit for publication.

3. RESULTS AND DISCUSSION

Of the 2,387 randomized children, exclusions were made for lack of HIV information at any time ($n=27$), baseline HIV-positivity ($n=264$), or lack of post-baseline HIV tests ($n=299$). Hence, 1,804 children were included in this analysis, of which 91 became HIV-infected during follow-up (Figure 1). At 6 weeks postnatal examination (baseline), clinical malaria was diagnosed in 172 HIV-negative infants, of whom only 49 and 15 had probable and confirmed malaria episodes, respectively. Other sociodemographic characteristics of the cohort at baseline (6 weeks) are given in Table 1.

Median breastfeeding duration for children who became postnatally HIV-positive and those persistently HIV-negative through the end of breastfeeding were 4.7 (variance =6.3) and 4.1 months (variance=5.9), respectively. During follow-up, clinical malaria was diagnosed by a physician in 594(33%) children (mean number of episodes=1.53, SD=0.89). Among these children, laboratory tests were requested for 283 children. However, the results were available for only 81 children, of whom 80 were positive for parasitemia. Median follow-up duration did not differ by postnatal HIV infection status at 5.9 (variance =3.4) months for children who became HIV-positive postnatally versus 5.9 (variance=5.7) months for HIV-uninfected children.

Ever vs. never child clinical, probable, and confirmed malarial morbidity were each positively associated with the risk of postnatal HIV infection; however, statistical significance was attained for clinical and probable malaria only (Table 2). Per episode increment, HIV postnatal infection risk increased by 39% (95%CI:8%-180%) for clinical malaria, 52% (95%CI:0%-232%) for probable malaria, and perhaps as high as 110% (95%CI:-9%-487%) for confirmed malaria episodes. Relative to children without clinical malaria, the risk of postnatal HIV infection increased in a dose-dependent manner for children with one, two, or three or more clinical malaria episodes. Likewise, a non-statistically significant trend of higher infection risk was evident for categorical comparisons of children with one or two or more versus zero confirmed malaria episodes. These associations were robust to adjustment for several indicators of maternal health status, socio-demographic characteristics, and child cotrimoxazole compliance and child baseline immunologic status (Table 2).

There was no relationship between postnatal HIV infection and child micronutrient supplementation (HR=0.98; 95%CI:0.64-1.49) or child baseline CD4%<25 (HR=1.28; 95%CI:0.77-2.14) level. Likewise, there was no association between child postnatal HIV infection risk and the following indicators of maternal health status: maternal malaria, maternal anemia status, or maternal ARV use (Table 3). However, poor maternal immunologic status, as indicated by CD4 T-cell count <350 vs. ≥ 350 cells/ μ l, was associated with a nearly three times higher risk of postnatal HIV infection. In comparison, current maternal ARV use exhibited a non-statistically protective association with child postnatal HIV infection (Table 3). We found no evidence of heterogeneity in the association between child malarial morbidity and postnatal HIV infection by maternal or child immunologic status, anemia, micronutrient supplementation, maternal enrolment in the pre vs. post-PEPFAR era, or child cotrimoxazole compliance.

DISCUSSION

253 We provide the first prospective evidence, to our knowledge, of an association between child
254 clinical and probable malarial morbidity and subsequent risk of postnatal HIV infection
255 among breastfeeding infants of HIV-positive women at high risk of acquiring both infections.
256 The risk of HIV infection increased by between 39% and 52%, and may possibly be as high
257 as 110%, for each additional episode of malaria. We found evidence of a dose-dependent
258 rise in risk of postnatal HIV infection for children with clinical and confirmed malaria relative
259 to children without malaria. Except for low maternal immunologic status, which was
260 associated with higher risk of postnatal HIV infection, other indicators of maternal health,
261 including maternal malaria, did not independently predict child postnatal HIV infection.

262 Our findings are consistent with the results of two epidemiologic studies conducted in Kenya.
263 The first, a simulation study of the consequence of extensive HIV and malaria overlap in
264 SSA, concluded that malaria and HIV interact non-additively and increase the burden of both
265 diseases in the region.(2) The second, an ecological study, found twice the odds of being
266 HIV-infected for adults who reside in high vs. low *P. falciparum* prevalence areas.(24)

267 *In vitro* studies of immune response to malaria and HIV infections provide biologically
268 plausible mechanisms in support of our finding that HIV-exposed sero-negative infants could
269 be at higher risk of HIV infection following bouts of malaria. First, CD4 T-cells, in which HIV
270 preferentially replicates, have a dual role in adaptive anti-malarial immune response, starting
271 with initial elaboration of pro-inflammatory cytokine expression(25, 26) and transitioning to
272 expansion of counter-regulatory anti-inflammatory cytokines through interaction with B-cells
273 to minimize the risk of developing complicated malaria.(27) The up-regulation of TNF- α and
274 other pro-inflammatory cytokines in response to acute malaria infections creates conditions
275 favorable to HIV acquisition,(28) as inflammatory cytokines act directly on the HIV long-
276 terminal repeats to up-regulate viral replication(29, 30) and to increase the population of cell
277 types (macrophages) susceptible to HIV infection.(31) Second, *in-utero* HIV exposure has
278 been associated with immune-dysregulations characterized by higher pro-inflammatory
279 cytokine expression during infancy relative to HIV unexposed neonates.(29) The extent of
280 immune-dysregulation is more profound for children whose mothers had detectable viral
281 loads during pregnancy.(32) We speculate that our finding of malaria-associated risk of HIV
282 infection in this sample is mediated through malaria-induced up-regulation of pro-
283 inflammatory cytokine responses, a phenomenon that limits the capacity of infants with
284 malaria to mount an effective counter-regulatory anti-inflammatory response and, thereby,
285 creates conditions favorable for HIV acquisition. Specific future studies are needed to
286 confirm or refute our findings and to elucidate the proximate mechanisms involved.

287 The key strengths of this study include its large sample size, prospective cohort design, an
288 analytic approach that restricted the relevant etiologic period for all children by breastfeeding
289 duration, and our ability to make within-person comparisons and have a tight control for
290 important baseline and time-varying confounders: breastfeeding duration, maternal and child
291 immunologic and anemia status, child cotrimoxazole compliance, nutritional status, low birth
292 weight, and socio-demographic characteristics. A major limitation of this study is the use of
293 physician-diagnosed clinical malaria. This definition of malarial morbidity, although reflective
294 of clinical practice in the area, overestimates malarial morbidity. We attempted to address
295 this limitation through sensitivity analyses that used progressively stringent malaria
296 diagnostic criteria. However, the number of malaria events declined steadily as diagnostic
297 specificity increased, which resulted in a limited power to detect associations between
298 confirmed child malaria episodes and postnatal HIV infection. This lack of precision is
299 reflected in the widening of confidence intervals for the most rigorous malaria diagnostic
300 category.

301 Another important limitation pertains to the 6-monthly timing of HIV tests, which made it
302 difficult to determine with precision the exact timing of HIV infection and raised the potential
303 of reverse causality for the malaria-HIV association. We addressed this issue analytically as
304 follows: (1) We restricted observations for malaria assessment in all infants regardless of
305 eventual HIV-infection status to visits that occurred on or before the end of breastfeeding;
306 and (2) We censored observations for HIV-infected children to the earlier of either the blood
307 sample acquisition date or the end of breastfeeding plus literature informed lag time for
308 detection of HIV-specific immune response. For example, for a given postnatally HIV-
309 infected infant, if the first sample that became HIV-positive was drawn at month 12, but the
310 infant was weaned at 5 months, the infant's effective HIV-positive date for analytic purposes
311 was age at weaning plus HIV sero-conversion window. We acknowledge these limitations,
312 which warrant cautious interpretation of our findings and stress the importance of future,
313 specifically-designed epidemiologic studies that use laboratory-confirmed malaria or malaria
314 rapid diagnostic tests to confirm or refute our findings that malarial morbidity may increase
315 the risk of HIV-acquisition among HIV-negative persons at risk of both HIV and malaria in co-
316 endemic settings. In spite of highlighted weaknesses, the internal consistency of our results
317 across diagnostic categories and their robustness to simultaneous control for a range of
318 confounders is suggestive of a possibly important role for malaria in HIV-acquisition. It
319 remains important to re-examine this hypothesis in a malaria endemic region among malaria
320 and HIV at risk populations.

321 We have shown that child clinical and probable malarial morbidity may be independent risk
322 factors for postnatal HIV infection in this cohort of breastfeeding children HIV-negative at 6
323 weeks, born to HIV-infected women. Both HIV-exposed and HIV-infected infants should be
324 actively evaluated for malaria infection and treated in a timely manner, when indicated as
325 part of routine medical care. The adoption of increased clinical vigilance, rather than passive
326 reliance on manifestation of malaria-related symptoms, which is currently the norm, will
327 complement malaria prevention strategies already in place. These strategies include
328 consistent use of insecticide-treated bed nets and malaria chemoprophylaxis of at-risk
329 individuals in regions of unstable malaria transmission by the timely removal of important
330 sources of systemic inflammatory responses that favor HIV acquisition in malaria and HIV
331 co-endemic settings.

332

333 **Figure 1 – Derivation of Analytic Sample**

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348




Table 1: Description of HIV-positive mothers and HIV-exposed but uninfected infants at mother's enrollment in the study enrollment, delivery or infants' sixth week of life (N = 1804 mother-child pairs)

	Mean (SD)
Child weight (kg) at 6 weeks	4.5 (0.7)
Child CD4 percent at 6 weeks	38.3(10.4)
Child absolute CD4 T-cell Count (cells/uL) at 6 weeks	2033 (4252)
	N (%)
Child Sex (male)	984(54.6)
Low Birth weight (< 2500g)	103 (5.9)
Underweight (WAZ <= -2) at 6 weeks	129 (7.3)
CD4 T-cell percent distribution at 6 weeks	
<15%	27 (1.8)
15 – 25%	110 (7.4)
>25%	1352 (90.8)
Malaria Diagnosis by 6 weeks	
Clinical Malaria	172 (9.5)
Probable Malaria	49 (2.7)
Confirmed Malaria	15 (0.8)
Maternal Characteristics at Enrollment	Mean (SD)
Maternal Age (years)	28.3 (5.0)
Maternal CD4 T-cell count (cell/uL)	550.2 (360.1)
Gravidity -including current child	2.6 (1.3)
Maternal Education (years)	7.1 (2.8)
	N (%)
Maternal History of >= 1 Neonatal Mortality*	319 (17.9)
Married/living with partner	1563 (87.6)
Household Daily Food expenditure <500 T Sh	1200 (66.5)
* Includes # of children born alive but died within 7 days or after 7 days	
Estimates based on 1703 to 1804 children, except for child Cd4 percent (n = 1489),	
absolute CD4 cell count (child = 1690, mother = 1618).	

350

351

Table 2: Child Malarial morbidity in relation to postnatal HIV infection among HIV-exposed infants of HIV-positive women from Dar es Salaam, Tanzania

	Univariate Model Hazard Ratio (95% CI)	Multivariable Model Hazard Ratio (95% CI)
Child Malarial Morbidity		
<i>Ever vs. Never Infection</i>		
Clinical Malaria	1.56 (1.02, 2.39)	1.73 (1.11, 2.69)
Probable Malaria	1.73 (1.05, 2.85)	2.00 (1.17, 3.42)
Confirmed Malaria	1.40 (0.51, 3.84)	2.09 (0.74, 5.91)
<i>Per episode increment</i>		
Clinical Malaria	1.31 (1.03, 1.67)	1.39 (1.08, 1.80)
Probable Malaria	1.35 (0.91, 1.99)	1.52 (1.00, 2.32)
Confirmed Malaria	1.43 (0.65, 3.17)	2.10 (0.91, 4.87)
<i>Number of Episodes</i>		
Clinical Malaria		
1 vs. 0	1.46 (0.90, 2.38)	1.66 (1.01, 2.72)
2 vs. 0	1.62 (0.79, 3.32)	1.64 (0.77, 3.45)
3+ vs. 0	2.25 (0.88, 5.73)	2.86 (1.07, 7.65)
Probable Malaria		
1 vs. 0	1.97 (1.17, 3.31)	2.20 (1.27, 3.82)
2+ vs. 0*	0.81 (0.20, 3.32)	1.07 (0.25, 4.52)
Confirmed Malaria		
1 vs. 0	1.20 (0.38, 3.81)	1.71 (0.53, 5.59)
2+ vs. 0*	2.84 (0.39, 20.84)	6.87 (0.89, 59.86)

Estimates are derived from Cox Proportional Hazards models where time to HIV infection is the dependent variable. The relative hazard of HIV incidence is estimated. CI = Confidence Intervals

In addition to the covariates shown above, the multivariable model adjusted for: child sex, micro-nutrient supplementation vs. Placebo, birth weight, per-capita household daily food expenditure, maternal age, maternal education, maternal history of neonatal mortality and child anemia status. All covariates are set to their values at the beginning of respective intervals.

*: Few children were diagnosed with three or more probable or confirmed malaria episodes while breastfeeding; therefore highest exposure category consists of two or more malaria episodes.

Table 3: Maternal health status indicators in relation to postnatal HIV infection among HIV-exposed infants of HIV-positive women from Dar es Salaam, Tanzania

	Univariate Model	Multivariate Model
Maternal Health Indicators	Hazard Ratio (95% CI)	Hazard Ratio (95% CI)
Ever vs. never clinical malaria	1.23 (0.78, 2.00)	1.03 (0.59, 1.79)
Current vs. never anemia	1.39 (0.91, 2.13)	1.14 (0.62, 2.10)
CD4 <350 vs. ≥ 350 cells/uL	3.45 (2.28, 5.24)	2.82 (1.75, 4.54)
Current vs. never ARV use	1.06 (0.49, 2.30)	0.62 (0.28, 1.42)

Estimates are derived from Cox Proportional Hazards models where time to child HIV infection is the dependent variable. The relative hazard of HIV incidence is estimated. CI = Confidence Intervals

In addition to above covariates, the multivariable model adjusted for: child malarial morbidity, child anemia, child sex, micro-nutrient supplementation vs. placebo, birth weight, per-capita household daily food expenditure, maternal age, maternal education and maternal history of neonatal mortality. All covariates are set to their values at the beginning of respective follow-up visits.

4. CONCLUSION

We have shown that child clinical and probable malarial morbidity may be independent risk factors for postnatal HIV infection in this cohort of breastfeeding children HIV-negative at 6 weeks, born to HIV-infected women. Both HIV-exposed and HIV-infected infants should be actively evaluated for malaria infection and treated in a timely manner, when indicated as part of routine medical care. The adoption of increased clinical vigilance, rather than passive reliance on manifestation of malaria-related symptoms, which is currently the norm, will complement malaria prevention strategies already in place. These strategies include consistent use of insecticide-treated bed nets and malaria chemoprophylaxis of at-risk individuals in regions of unstable malaria transmission by the timely removal of important sources of systemic inflammatory responses that favor HIV acquisition in malaria and HIV co-endemic settings.

ACKNOWLEDGEMENTS

Funding

This work was supported by the National Institute of Child Health and Human Development Grant#: R01HD043688. CD was supported in part by K24 HD058795.

We thank the study participants from Dar es Salaam, Tanzania for making this study possible. We are grateful to the field staff for their diligence and energy: Rehema Mtonga, Illuminata Ballonzi, Godwin Njiro, Frank Killa, Emily Dantzer, Elizabeth Long and Jenna Golan. Dr. Ezeamama acknowledges, with thanks, support from the Harvard School of Public Health Yerby Post-doctoral Fellowship program.

The opinions and statements in this article are those of the authors and may not reflect official UNICEF policies.

COMPETING INTERESTS

Conflict of Interest Statement

The authors do not have commercial (e.g., pharmaceutical stock ownership, consultancy) or other associations that pose a conflict of interest in the collection, analysis, presentation and interpretation of this data.

Role of Funding Source

The funder of this study had no role in the design, data collection, analysis, interpretation, or writing of this report. The corresponding author had full access to all the data in the study and had the final responsibility for the decision to submit for publication.

AUTHORS' CONTRIBUTIONS

All co-authors have seen and approved the content of this article. Each has participated in the concept and design, analysis, data interpretation, writing or revision of this manuscript. We did not receive any external writing assistance in the development of this manuscript.

INFORMED CONSENT AND ETHICAL APPROVAL

Ethical clearance for the conduct of this study was provided by the institutional review boards of the Harvard School of Public Health and Muhimbili University of Health and Allied Sciences. The mothers of all children provided written informed consents for their own and their child's participation in the trial.

All authors hereby declare that all experiments have been examined and approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

REFERENCES

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT and Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet*. 2006; **367**:1747-57.

- 428 2. Abu-Raddad LJ, Patnaik P and Kublin JG. Dual infection with HIV and malaria fuels
429 the spread of both diseases in sub-Saharan Africa. *Science (New York, NY)*. 2006; **314**:1603-
430 6.
- 431 3. Kanya MR, Gasasira AF, Yeka A, et al. Effect of HIV-1 infection on antimalarial
432 treatment outcomes in Uganda: a population-based study. *The Journal of infectious
433 diseases*. 2006; **193**:9-15.
- 434 4. Hewitt K, Steketee R, Mwapasa V, Whitworth J and French N. Interactions between
435 HIV and malaria in non-pregnant adults: evidence and implications. *AIDS (London,
436 England)*. 2006; **20**:1993-2004.
- 437 5. Foca E, Odolini S, Brianese N and Carosi G. Malaria and hiv in adults: when the
438 parasite runs into the virus. *Mediterranean journal of hematology and infectious diseases*.
439 2012; **4**:e2012032.
- 440 6. Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on
441 concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort
442 study. *Lancet*. 2005; **365**:233-40.
- 443 7. Mermin J, Ekwaru JP, Liechty CA, et al. Effect of co-trimoxazole prophylaxis,
444 antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-
445 infected adults in Uganda: a prospective cohort study. *Lancet*. 2006; **367**:1256-61.
- 446 8. Steiner K, Myrie L, Malhotra I, et al. Fetal immune activation to malaria antigens
447 enhances susceptibility to in vitro HIV infection in cord blood mononuclear cells. *The Journal
448 of infectious diseases*. 2010; **202**:899–907.
- 449 9. Xiao L, Owen SM, Rudolph DL, Lal RB and Lal AA. Plasmodium falciparum antigen-
450 induced human immunodeficiency virus type 1 replication is mediated through induction of
451 tumor necrosis factor-alpha. *The Journal of infectious diseases*. 1998; **177**:437-45.
- 452 10. Mellors JW, Griffith BP, Ortiz MA, Landry ML and Ryan JL. Tumor necrosis factor-
453 alpha/cachectin enhances human immunodeficiency virus type 1 replication in primary
454 macrophages. *The Journal of infectious diseases*. 1991; **163**:78–82.
- 455 11. Moriuchi M, Moriuchi H, Mon HM and Kanbara H. Dichotomous effects of
456 Plasmodium falciparum antigens on expression of human immunodeficiency virus (HIV)
457 coreceptors and on infectability of CD4 cells by HIV. *The Journal of infectious diseases*.
458 2002; **186**:1194–7.
- 459 12. UNAIDS. Global Report: UNAIDS report on the global AIDS epidemic 2010: Joint
460 United Nations Programme on HIV/AIDS. 2011.
- 461 13. Hofmann J, De Allegri M, Sarker M, Sanon M and Bohler T. Breast milk as the
462 "water that supports and preserves life"--socio-cultural constructions of breastfeeding and
463 their implications for the prevention of mother to child transmission of HIV in sub-Saharan
464 Africa. *Health policy (Amsterdam, Netherlands)*. 2009; **89**:322-8.
- 465 14. Vora N, Homsy J, Kakuru A, et al. Breastfeeding and the risk of malaria in children
466 born to HIV-infected and uninfected mothers in rural Uganda. *Journal of acquired immune
467 deficiency syndromes (1999)*. 2010; **55**:253–61.

- 468 15. WHO. New guidance on prevention of mother-to-child transmission of HIV and infant
469 feeding in the context of HIV. 2010.
- 470 16. Geissbuhler Y, Kannady K, Chaki PP, et al. Microbial larvicide application by a
471 large-scale, community-based program reduces malaria infection prevalence in urban Dar es
472 Salaam, Tanzania. *PloS one*. 2009; **4**:e5107.
- 473 17. WHO. World Malaria Report 2010. WHO, 2011.
- 474 18. TACAIDS. UNGASS Country Progress Report: Tanzania Mainland. 2008.
- 475 19. Ezeamama AE, Spiegelman D, Hertzmark E, et al. HIV Infection and the incidence
476 of malaria among HIV-exposed children from Tanzania. *The Journal of infectious diseases*.
477 2012; **205**:1486-94.
- 478 20. Tangpukdee N, Duangdee C, Wilairatana P and Krudsood S. Malaria diagnosis: a
479 brief review. *The Korean journal of parasitology*. 2009; **47**:93–102.
- 480 21. Patnaik P, Jere CS, Miller WC, et al. Effects of HIV-1 serostatus, HIV-1 RNA
481 concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults
482 in rural Malawi. *The Journal of infectious diseases*. 2005; **192**:984-91.
- 483 22. Aboud S, Urassa W, Lyamuya E, Mhalu F and Biberfeld G. Evaluation of HIV
484 antibody and antigen/antibody combination ELISAs for use in an alternative confirmatory HIV
485 testing strategy in Dar es Salaam, Tanzania. *Journal of virological methods*. 2006; **135**:192-
486 6.
- 487 23. Lindback S, Thorstensson R, Karlsson AC, et al. Diagnosis of primary HIV-1
488 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV
489 Infection Study Group. *AIDS (London, England)*. 2000; **14**:2333–9.
- 490 24. Cuadros DF, Branscum AJ and Crowley PH. HIV-malaria co-infection: effects of
491 malaria on the prevalence of HIV in East sub-Saharan Africa. *International journal of*
492 *epidemiology*. 2011; **40**:931–9.
- 493 25. Artavanis-Tsakonas K and Riley EM. Innate immune response to malaria: rapid
494 induction of IFN-gamma from human NK cells by live *Plasmodium falciparum*-infected
495 erythrocytes. *J Immunol*. 2002; **169**:2956-63.
- 496 26. Walther M, Woodruff J, Edele F, et al. Innate immune responses to human malaria:
497 heterogeneous cytokine responses to blood-stage *Plasmodium falciparum* correlate with
498 parasitological and clinical outcomes. *J Immunol*. 2006; **177**:5736–45.
- 499 27. Leoratti FM, Durlacher RR, Lacerda MV, et al. Pattern of humoral immune response
500 to *Plasmodium falciparum* blood stages in individuals presenting different clinical
501 expressions of malaria. *Malaria journal*. 2008; **7**:186.
- 502 28. Stevenson MM and Riley EM. Innate immunity to malaria. *Nature reviews*. 2004;
503 **4**:169-80.
- 504 29. Breen EC. Pro- and anti-inflammatory cytokines in human immunodeficiency virus
505 infection and acquired immunodeficiency syndrome. *Pharmacology & therapeutics*. 2002;
506 **95**:295–304.

- 507 30. Poli G, Pantaleo G and Fauci AS. Immunopathogenesis of human immunodeficiency
508 virus infection. *Clin Infect Dis*. 1993; **17 Suppl 1**:S224–9.
- 509 31. Renia L and Potter SM. Co-infection of malaria with HIV: an immunological
510 perspective. *Parasite immunology*. 2006; **28**:589–95.
- 511 32. Hygino J, Lima PG, Filho RG, et al. Altered immunological reactivity in HIV-1-
512 exposed uninfected neonates. *Clinical immunology (Orlando, Fla)*. 2008; **127**:340-7
513
514